Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Takeda Pharmaceutical Company Limited

< Previous 1 2 3 4 5 6 Next >
Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology (ASH) Annual Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda’s LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages 12 Years and Older With Post-Transplant Cytomegalovirus (CMV) Infection/Disease in the United States
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social Disparities
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda’s LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Recommends Common-sense Policy Reforms Designed to Reduce Time to Diagnosis, Improve Access to Care for Patients with Rare Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Applied for Selection of “Prime Market”, Filed Corporate Governance Report With Tokyo Stock Exchange (TSE) in Line With Revised Corporate Governance Code and Published Corporate Governance Related Documents on its Website
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Acquisition of Own Shares
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global Brands
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
BioLife Plasma Services Announces Expansion of Plasma Donation Centers into Massachusetts
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Provides Update on TAK-994 Clinical Program
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
BioLife Plasma Services Opens First All-Electric Plasma Donation Center
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding Disorders
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces the Submission of Its Corporate Governance Report to the Tokyo Stock Exchange
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2020
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
New Data from the Phase 3 HELP Study™ Open-Label Extension Evaluating Safety and Efficacy of TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Phase 3 Clinical Trial Subgroup Analysis Across Solid Organ Transplant (SOT) Types Supports Efficacy of Maribavir Over Conventional Therapies in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treatment
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.